Mani Foroohar
Stock Analyst at Leerink Partners
(1.64)
# 2,994
Out of 4,814 analysts
173
Total ratings
43.62%
Success rate
-11.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $2.71 | +564.21% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $5.50 | +9.09% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $3.06 | +782.35% | 9 | Jan 13, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $46 → $44 | $6.33 | +595.10% | 10 | Nov 19, 2024 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $11.49 | +526.63% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $1.91 | +790.05% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $38.63 | +26.84% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $34.24 | +34.35% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $5.92 | +271.62% | 6 | Oct 16, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $28.32 | +118.93% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $13.58 | -4.27% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $25.21 | +15.03% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $53.79 | +327.59% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $3.14 | +27.59% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $5.96 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $4.00 | +675.00% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.45 | +1,455.56% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $11.21 | +256.82% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $24.73 | +276.14% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $7.27 | +1,056.23% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $1.29 | +444.75% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $180 → $160 | $4.15 | +3,755.42% | 10 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $16.25 | +373.85% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $234.75 | -39.08% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $4.84 | +23.97% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $37.76 | +101.27% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $0.74 | +4,480.36% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $2.91 | +588.47% | 6 | Jul 23, 2021 |
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $2.71
Upside: +564.21%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $5.50
Upside: +9.09%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $3.06
Upside: +782.35%
Rocket Pharmaceuticals
Nov 19, 2024
Maintains: Outperform
Price Target: $46 → $44
Current: $6.33
Upside: +595.10%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $11.49
Upside: +526.63%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $1.91
Upside: +790.05%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $38.63
Upside: +26.84%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $34.24
Upside: +34.35%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $5.92
Upside: +271.62%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $28.32
Upside: +118.93%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $13.58
Upside: -4.27%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $25.21
Upside: +15.03%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $53.79
Upside: +327.59%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $3.14
Upside: +27.59%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $5.96
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $4.00
Upside: +675.00%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.45
Upside: +1,455.56%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $11.21
Upside: +256.82%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $24.73
Upside: +276.14%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $7.27
Upside: +1,056.23%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $1.29
Upside: +444.75%
Jan 23, 2023
Maintains: Market Perform
Price Target: $180 → $160
Current: $4.15
Upside: +3,755.42%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $16.25
Upside: +373.85%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $234.75
Upside: -39.08%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $4.84
Upside: +23.97%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $37.76
Upside: +101.27%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $0.74
Upside: +4,480.36%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $2.91
Upside: +588.47%